The FDA has granted orphan drug designation to Soligenix for its treatment of Behçet's disease, a rare and chronic condition. This designation will help expedite the development and review process for the drug.

Editor’s Note: This is significant because orphan drug designation can provide Soligenix with various benefits, including tax credits and market exclusivity, which can accelerate the availability of new treatments for patients suffering from Behçet's disease.